Although figures not that good as expected still very good story behind the company and holding breakout position after earnings miss. (CELG believes Otezla has achieved a market share lead for psoriatic arthritis shortly after its launch in April). Good fancy LT Buy and Hold. Downside limited.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.